Aurion Biotech Initiates Dosing in Phase 3 ASTRA Study Evaluating AURN001 for Corneal Edema Secondary to Corneal Endothelial Dysfunction
Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company focused on restoring vision and addressing corneal blindness, has announced a key clinical milestone with the dosing of the first patients in the United States as part of its ASTRA Phase 3 pivotal study evaluating AURN001. The investigational therapy is being developed as a single-administration regenerative cell therapy intended to treat corneal edema secondary to corneal endothelial dysfunction, a condition that can significantly impair vision and quality of life.
The initiation of patient dosing in the Phase 3 ASTRA study represents an important step forward in the clinical development of AURN001 and marks progress toward potential regulatory submission in the United States. If approved, AURN001 could become the first cell therapy available in the U.S. for the treatment of corneal endothelial disease, offering a novel alternative to current surgical approaches.
Corneal endothelial dysfunction, including conditions such as Fuchs endothelial corneal dystrophy, is a progressive disorder characterized by the loss or dysfunction of corneal endothelial cells. These cells play a critical role in maintaining corneal hydration and transparency. When they fail, fluid accumulates in the cornea, leading to swelling (edema), blurred vision, glare, and in advanced cases, significant vision impairment. Current standard-of-care treatments often involve surgical intervention, including endothelial keratoplasty procedures, which replace damaged corneal tissue with donor grafts.
While modern surgical techniques such as endothelial keratoplasty have significantly improved outcomes compared to earlier approaches, limitations remain. These include reliance on donor tissue availability, the complexity of surgical procedures, potential graft rejection, and post-operative complications. Aurion Biotech aims to address these challenges by developing a regenerative cell therapy that restores corneal function without requiring traditional donor tissue transplantation.
Edward J. Holland, MD, Chief Medical Officer of Aurion Biotech, emphasized the significance of initiating the Phase 3 study and its potential implications for patients and clinicians. He noted that dosing the first participants in the ASTRA trial represents a meaningful milestone in the company’s broader effort to develop innovative treatments for vision loss caused by corneal endothelial disease. According to Holland, while existing surgical options have transformed patient care, there remains a need to improve outcomes, reduce complications, and enhance the overall patient experience. AURN001 is designed to represent a new therapeutic paradigm by shifting from donor tissue-based graft surgery to a cultured cell therapy approach aimed at restoring corneal clarity.
The ASTRA study is being conducted across multiple clinical sites in the United States, and the successful enrollment and treatment of the first patients reflect the coordinated efforts of investigators, clinical staff, and research institutions participating in the trial. Eris Jordan, OD, Chief Development Officer at Aurion Biotech, highlighted the importance of these investigative sites in advancing the program. She noted that the dedication and scientific rigor demonstrated by clinical investigators have been instrumental in enabling the study’s initiation. Jordan also emphasized that the enthusiasm surrounding the trial reflects a broader belief within the ophthalmology community that regenerative cell therapies have the potential to fundamentally change the treatment landscape for corneal diseases.
AURN001 is a first-in-class investigational combination therapy that incorporates unmodified human corneal endothelial cells, referred to as neltependocel, along with a rho-kinase inhibitor known as Y-27632. The therapy is administered via intracameral injection, a minimally invasive procedure that delivers the cells directly into the anterior chamber of the eye. Once administered, the therapy is designed to support the regeneration of the corneal endothelium, ultimately restoring corneal clarity and improving visual function.
The inclusion of a rho-kinase inhibitor is intended to enhance cell adhesion, proliferation, and survival, thereby improving the therapeutic potential of the transplanted endothelial cells. This combination approach is central to Aurion Biotech’s strategy of leveraging both cellular therapy and pharmacological support to achieve durable clinical outcomes. By enabling the regeneration of functional endothelial tissue, AURN001 has the potential to reduce or eliminate the need for donor corneal grafts in certain patients, thereby addressing limitations associated with current surgical interventions.
Arnaud Lacoste, PhD, MBA, Chief Executive Officer and Chief Scientific Officer of Aurion Biotech, described the initiation of the Phase 3 study as a foundational step toward the company’s planned Biologics License Application (BLA) submission in the United States. He emphasized that the ASTRA trial represents a critical component of Aurion’s mission to address a substantial global unmet medical need in corneal endothelial disease. Lacoste noted that the company’s approach involves using donor corneas as a source of endothelial cells to create a scalable and transportable cell therapy platform, thereby overcoming the logistical and supply limitations associated with traditional corneal transplantation.
Aurion Biotech has previously achieved clinical and commercial progress in other markets, including Japan, where its regenerative cell therapy approach has been evaluated. Building on these experiences, the company is now focused on expanding its clinical development efforts in the United States and advancing toward potential regulatory approval. The outcomes of the ASTRA Phase 3 study will play a pivotal role in supporting the company’s regulatory strategy and determining the safety and efficacy profile of AURN001 in a broader patient population.
The ASTRA clinical trial is currently underway in the United States, with additional information available through clinical trial registries and the company’s dedicated trial website. The study is designed to evaluate key endpoints related to safety, tolerability, and efficacy, including improvements in corneal clarity and visual acuity. As a pivotal Phase 3 trial, ASTRA is intended to generate the data required to support regulatory submissions and potential commercialization efforts.
The development of AURN001 reflects a broader trend in regenerative medicine and ophthalmology toward cell-based therapies that aim to repair or replace damaged tissues rather than relying solely on surgical intervention. If successful, this approach could represent a significant advancement in the treatment of corneal endothelial diseases and potentially reduce the global burden of vision loss associated with these conditions.
As Aurion Biotech continues to advance its clinical program, the company remains focused on executing the ASTRA study, generating robust clinical data, and preparing for future regulatory interactions. The dosing of the first patients in the Phase 3 trial marks the beginning of a critical phase in the development of AURN001 and underscores the company’s commitment to bringing innovative regenerative therapies to patients with unmet medical needs in ophthalmology.
About ASTRA Phase 3 Study
Patients will be enrolled at 12 sites across the U.S. and randomized to AURN001 + Y-27632. The primary endpoint is the percentage of participants who achieve a ≥ 15-letter improvement (3-line gain) from baseline in Best Corrected Visual Acuity (BCVA) at Month 6. Secondary endpoints are changes from baseline in non-contact Central Corneal Thickness (CCT) at Month 6 and change from baseline in BCVA at Month 6.
About Corneal Endothelial Cell Therapy (CECT)
Aurion Biotech is advancing Corneal Endothelial Cell Therapy (CECT), a regenerative treatment that aims to replace lost or dysfunctional endothelial cells. Because endothelial cells cannot naturally regenerate, patients experience progressive vision loss. The cells delivered to patients are human corneal endothelial cells obtained from donated corneas. They do not contain any synthetic materials or artificial scaffold. The cells do not undergo genetic reprogramming. Aurion’s cells are intended to repopulate the endothelium and help re-establish a corneal structure that is virtually indistinguishable from a healthy cornea with healthy fluid balance.
About Aurion Biotech
Aurion’s mission is to restore vision to millions of patients with life-changing regenerative therapy. Aurion is a commercial stage company in Japan and a clinical stage company in Phase 3 development in the U.S. The company is developing AURN001, an investigational, single-administration, allogeneic cell therapy for corneal endothelial disease, a condition that causes progressive vision loss in millions of patients worldwide. In 2024, Aurion launched Vyznova™, the first cell therapy for corneal endothelial disease commercially available in Japan. Aurion received the prestigious Prix Galien award for Best Start-Up in Biotech in 2022 and was named to Fast Company’s annual list of Most Innovative Companies in 2025. In 2025, Alcon acquired majority ownership of Aurion Biotech.
Source Link:https://www.businesswire.com/
